Trial Profile
A phase 2, multi-centre, randomised, double blind, placebo controlled study evaluating the efficacy, safety and pharmacokinetics of two doses of a candidate disease modifying anti-rheumatic drug (DMARD), (SMP-114 120 mg and 240 mg once daily), administered in combination with ongoing methotrexate treatment in patients with active rheumatoid arthritis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2019
Price :
$35
*
At a glance
- Drugs Rimacalib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ASPECTS
- Sponsors Sumitomo Pharma
- 10 Sep 2019 Planned End Date changed from 1 Jun 2008 to 21 Jul 2008.
- 29 Jan 2015 Status changed from discontinued to completed as per ISRCTN: Current Controlled Trials.
- 22 Aug 2007 Status changed from recruiting to in progress.